Development of Carbon Monoxide Releasing Molecules for the Treatment of Postoperative Ileus
The biotechnology company Alfama, with sites in Lisbon and Boston, is the world leader in CO-releasing molecules (CORMs), compounds with powerful vasodilatation activity. GalChimia has partnered with Alfama to develop CORMs for Postoperative Ileus (POI), a condition usually found in patients who have undergone surgery. GalChimia’s synthetic expertise complements the Alfama’s deep biological knowledge of CORMs.
The project received funding from the European Eurostars Program for SMEs.
GalChimia thanks all the partners in the CORMPOI project for their involvement and teamwork, which have been key to the success of the project.
